Dr. William A. Rollefson, MD

Dr. Rollefson practices at Arkansas Heart Hospital in Little Rock, Arkansas, part of Arkansas Heart Hospital.

Dr. Rollefson's NPI, 1366436750, was assigned on August 31, 2005. Dr. Rollefson graduated from University of Arkansas College of Medicine in 1994. Dr. Rollefson holds Arkansas license C8143.

Dr. Rollefson's primary practice is Arkansas Heart Hospital, at 1701 S Shackleford Road, Little Rock, AR 72211 in Pulaski County. The practice phone is (501) 219-7000.

Dr. Rollefson's primary practice is Arkansas Heart Hospital in Little Rock, Arkansas, part of Arkansas Heart Hospital. Dr. Rollefson is also affiliated with Baptist Health Medical Center-Little Rock. The medical group on file is Arkansas Heart Hospital Clinic (Little Rock Clinic). Dmand AI also links Dr. Rollefson to 3 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rollefson practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Rollefson's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Rollefson is licensed in Arkansas.

CMS data shows 2,942 Medicare services from Dr. Rollefson across 33 procedure codes in 2024, for 1,159 Medicare patients. Medicare paid $183,125 for them.

CMS counts 1,159 Medicare patients who saw Dr. Rollefson in 2024. The largest group is 75 to 84, with 501 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rollefson's median patient age at 76, with 48% women.

In 2024, Dr. Rollefson wrote 7,117 Medicare Part D claims for 906 patients. 92% of them were for generic drugs. CMS names the drug for 6,812 of them, across 59 drugs with 11 or more claims each, at $537,519 in total drug cost. In 2023, CMS named 6,566 claims across 63 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Rollefson for performance year 2024, reported as part of a group. Dr. Rollefson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 42 procedures of coronary angioplasty and stenting by Dr. Rollefson, more than 78% of the clinicians it reports for that procedure.

Dmand AI links 8 papers to Dr. Rollefson, published from 2013 to 2024. 2018 was the busiest year, with 2. The most frequent topics are Radial Artery, Femoral Artery and Heart Failure. Dr. Rollefson has published most often in Cardiovasc Revasc Med. Dr. Rollefson's most frequent co-authors are David M. Mego, MD, Konstantinos Marmagkiolis, MD and Ian M. Cawich, MD.

CMS Open Payments shows 370 general payments to Dr. Rollefson from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. Terumo Medical Corporation paid the most, $90,662.

Dr. Rollefson graduated from University of Arkansas College of Medicine in 1994.